Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A.
Raje NS, et al. Among authors: wooldridge je.
Br J Haematol. 2017 Mar;176(5):783-795. doi: 10.1111/bjh.14483. Epub 2016 Dec 22.
Br J Haematol. 2017.
PMID: 28005265
Free article.
Clinical Trial.